Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propranolol
Drug ID BADD_D01867
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status approved; investigational
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D08443
MeSH ID D011433
PubChem ID 4946
TTD Drug ID D04JEE
NDC Product Code Not Available
UNII 9Y8NXQ24VQ
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H21NO2
CAS Registry Number 525-66-6
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachypnoea22.02.01.0140.000160%-
Tearfulness19.15.02.0050.000080%-
Teething07.09.05.0050.000662%-
Telangiectasia23.06.03.001; 24.03.03.0030.000053%
Tension headache17.14.01.004; 19.24.01.009---
Therapeutic response unexpected08.06.01.0010.000262%-
Throat tightness19.01.02.005; 22.12.03.0310.000144%-
Thrombocytopenic purpura01.08.01.003; 23.06.01.007---
Thyroid disorder05.02.01.0020.000053%-
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.0090.000053%-
Tonic convulsion17.12.03.0110.000053%-
Tooth discolouration07.09.02.0010.000182%
Torsade de pointes02.03.04.0050.000374%-
Toxic encephalopathy12.03.01.027; 17.13.01.0040.000080%-
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Ulcer08.03.06.0010.000475%-
Unresponsive to stimuli17.02.05.0310.000614%-
Urinary incontinence17.05.01.008; 20.02.02.0100.000080%
Urticaria10.01.06.001; 23.04.02.001--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Vasoconstriction23.06.05.007; 24.04.03.0080.000262%-
Ventricular arrhythmia02.03.04.0060.000214%
Ventricular extrasystoles02.03.04.0070.000160%-
Ventricular fibrillation02.03.04.0080.000240%
Ventricular tachycardia02.03.04.0100.000214%
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.007404%
Vomiting projectile07.01.07.0120.000272%-
Weight gain poor14.03.02.0180.000326%-
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene